Osteoporotic fractures are associated with significant morbidity and mortality. In addition, the declines in physical function and the changes in appearance due to fractures contribute to the severe reduction in patients' quality of life (HRQOL). It has been demonstrated that patients suffering subclinical fractures experience a reduction in their HRQOL. Some studies have also suggested that osteoporotic patients without fractures perceive a reduction in their quality of life. It has been suggested that anti- osteoporotic therapy is effective in increasing patients' HRQOL. In our clinical experience, treatment with teriparatide is effective in reducing back pain and in enhancing patients' activities of daily living.